Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

COVID-19 Clinical Trial

— MELCOVID  

Official title:

A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04568863
• Other study ID #: PHM-2020-001
• Status: Completed
• Phase: Phase 2
• Start date: June 20, 2020
• Est. completion date: November 30, 2020

Study information

• Verified date: September 2020
• Source: Pharmamel S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects. This randomized controlled trial seeks to evaluate the efficacy of intravenous melatonin in reducing mortality in Covid-19 patients in the ICUs.

Description:

ICU COVID-19 patients show high risk of death mainly due to sepsis and respiratory disfunction. Prevention of these critical conditions is mandatory to reduce mortality and to improve patient's outcome.

Melatonin is an endogenous hormone involved not only in circadian rhythm control, but also in the cell protection due to its outstanding anti-inflammatory and antioxidative effects. High doses of melatonin have shown high efficacy against bacterial (sepsis) and viral infections. Melatonin is a safe product that consistently has shown lack of side-effects when it is administered to humans.

SARS-CoV 2 infection may yield severe forms of the disease that require the patients admission to the ICU. These patients may develop an excessive inflammatory response and a burst of free radicals, constituting the major cause of death in these subjects.

Our hypothesis is that high doses of melatonin intravenously administered to COVID-19 ICU patients might reach enough blood levels able to prevent/counteract the developing of sepsis and the production of free radicals, reducing mortality and hospital stay.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: November 30, 2020
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient, family member or legal guardian has provided written Informed Consent.

• Age e 18 years.

• Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR.

• Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection.

• ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission).

Exclusion Criteria:

• Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization.

• Liver enzymes > 5 times the upper normal range.

• Chronic kidney disease with GFR < 30 mL/min/1.73 m2 (stage 4 or greater) or need for hemodialysis.

• Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion.

• Terminal surgical or medical illness.

• Autoimmune disease.

• Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.

Related Conditions & MeSH terms

• Coronavirus Infection
• Coronavirus Infections
• COVID-19
• SARS-CoV 2
• Severe Acute Respiratory Syndrome

Intervention

Drug:
• Melatonin intravenous
7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
• Placebo intravenous
7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.

Locations

Country	Name	City	State
Spain	Hospital Universitario La Paz	Madrid

Sponsors (3)

Lead Sponsor	Collaborator
Pharmamel S.L.	Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Acuña-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña-Fernández C. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020 Oct;69(3):e12683. doi: 10.1111/jpi.12683. Epub 2020 Aug 8. — View Citation

Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	Mortality in each study group represented in frequency and time-to-event at day 28 after randomization	one month